logo
AF
Andrew Fein
Analyst at H.C. Wainwright
USA
Ticker Coverage
ACIU
Sector Coverage
Mentions in the News
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. Cantor Fitzgerald analyst Alethia Young maintained a Neutral rating and $300 price …
Published: Dec 6 2019
How Much Higher Can Amarin (AMRN) Stock Go Following FDA Approval?
Amarin (AMRN) investors received a nice gift going into the weekend, after shares of the biopharma increased by almost 12% on Friday. The boost came on the heels of Thursday’s FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vasc…
Published: Nov 18 2019
Would you like to be included in the directory? Let us know!
exchange@streetcontxt.com
© Street Contxt. All Rights Reserved.
Privacy